An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination
Duration of study (approximately 2.5 years)
Yes
GSK Clinical Trials
Study Director
GlaxoSmithKline
European Union: European Medicines Agency
113486
NCT01192165
September 2010
July 2013
Name | Location |
---|---|
GSK Investigational Site | Phoenix, Arizona 85013 - 4496 |
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Fort Worth, Texas 76104 |
GSK Investigational Site | Columbia, South Carolina 29210 |
GSK Investigational Site | Germantown, Tennessee 38138 |
GSK Investigational Site | Salem, Virginia 24153 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Aurora, Colorado 80012 |
GSK Investigational Site | Henderson, Nevada 89014 |
GSK Investigational Site | Seattle, Washington 98133 |